Mitochondria are often called the powerhouses of the cell, but recent research has revealed they do far more than generate energy. Buried within the compact 16,569-base-pair mitochondrial genome are small open reading frames (sORFs) that encode a newly recognized class of bioactive signaling molecules called mitochondrial-derived peptides (MDPs). These microproteins—including humanin, MOTS-c, and the small humanin-like peptides (SHLPs)—have emerged as key regulators of metabolism, stress response, and cellular resilience.
Since the discovery of humanin in 2001, the MDP field has expanded rapidly. Researchers have now identified at least nine distinct MDPs, each with unique biological activities that span neuroprotection, insulin sensitization, and exercise-mimetic effects. This article explores what we know about these fascinating molecules and where the research is heading.
All compounds referenced in this article are intended for research purposes only and are not approved for human or animal use. Nothing in this article constitutes medical advice.
The story of MDPs began when Hashimoto and colleagues screened for genetic factors that protected neurons against amyloid-beta toxicity—a hallmark of Alzheimer’s disease pathology. They identified a cDNA fragment that mapped to the mitochondrial 16S ribosomal RNA gene (MT-RNR2), encoding a 24-amino-acid peptide they named humanin (1). This was groundbreaking: the mitochondrial genome, long assumed to encode only 13 proteins plus transfer and ribosomal RNAs, contained hidden peptide-coding sequences.
The next major breakthrough came in 2015 when Kim et al. discovered MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c), a 16-amino-acid peptide encoded by a sORF within the 12S rRNA gene (MT-RNR1) (2). Shortly after, Cobb et al. (2016) identified six additional peptides within the 16S rRNA gene, naming them small humanin-like peptides 1 through 6 (SHLP1–6) (3). Computational analyses suggest that hundreds of additional MDPs may remain undiscovered within mitochondrial sequences (4).
MOTS-c: The Exercise Mimetic
Among all MDPs, MOTS-c has generated particular excitement for its remarkable metabolic effects. Research demonstrates that MOTS-c functions as an endogenous exercise mimetic, activating many of the same cellular pathways triggered by physical activity.
The primary mechanism involves the folate-AICAR-AMPK pathway. MOTS-c inhibits the folate cycle and de novo purine biosynthesis, leading to accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), a potent endogenous activator of AMP-activated protein kinase (AMPK) (5). Under metabolic stress, MOTS-c translocates to the nucleus where it regulates gene expression through antioxidant response elements (AREs), modulating stress adaptation and metabolic homeostasis (6).
In preclinical models, MOTS-c administration prevented high-fat-diet-induced obesity and insulin resistance in mice, while also improving glucose tolerance and reducing fat accumulation (2). A landmark 2021 study published in Nature Communications demonstrated that exercise induces endogenous MOTS-c expression in both skeletal muscle and circulation, and that late-life MOTS-c treatment (initiated at 23.5 months in mice) significantly improved physical capacity and healthspan markers (7). Circulating MOTS-c levels decline with age in humans and correlate positively with metabolic health indicators (8).
Research has also expanded into oncology: a 2024 study in Advanced Science found that MOTS-c suppresses ovarian cancer progression by attenuating USP7-mediated LARS1 deubiquitination, opening a new avenue of investigation (9).
These compounds are sold for laboratory research use only. They are not intended for human consumption, therapeutic use, or any form of self-administration.
Humanin: The Original Neuroprotector
Humanin remains the most extensively studied MDP, with over two decades of research documenting its cytoprotective properties. This 24-amino-acid peptide operates through both intracellular and extracellular mechanisms:
Intracellularly, humanin inhibits pro-apoptotic proteins including Bax and IGFBP3, enhances chaperone-mediated autophagy, and activates cell survival signaling cascades (10).
Extracellularly, humanin binds a trimeric receptor complex (CNTFR/WSX-1/gp130) and formyl peptide receptors, triggering downstream protective signaling. It also interacts directly with amyloid-beta, preventing fibril formation (10).
In C. elegans, overexpression of humanin extends lifespan through FOXO-dependent mechanisms (8). In mouse models, humanin treatment improves metabolic healthspan parameters, reduces inflammatory markers, and offers protection against age-related cognitive decline. Plasma humanin levels decrease significantly with age in humans, and lower levels are associated with type 2 diabetes and cardiovascular dysfunction (8, 11).
Humanin analogues such as HNG (a potent synthetic variant) and colivelin (a hybrid peptide) show enhanced neuroprotective activity in preclinical Alzheimer’s and Parkinson’s disease models, with researchers actively investigating their therapeutic potential (10).
The six small humanin-like peptides (SHLP1–6) represent the newest additions to the MDP family. While research is still in its early stages, several intriguing findings have emerged:
SHLP2 has received the most attention. A 2023 Nature Communications study revealed that SHLP2 regulates energy homeostasis by binding chemokine receptor 7 (CXCR7) and activating pro-opiomelanocortin (POMC) neurons in the hypothalamic arcuate nucleus, suppressing food intake and promoting thermogenesis (12). Both systemic and intracerebroventricular SHLP2 administration protected mice from high-fat-diet-induced obesity and improved insulin sensitivity. SHLP2 also exhibits chaperone-like activity and reduces amyloid-beta toxicity in vitro (3).
SHLP3 supports mitochondrial health by reducing reactive oxygen species (ROS), promoting adipocyte differentiation, and downregulating metabolic and inflammatory markers (8). In contrast, SHLP6 appears to promote apoptosis, and evolutionary analysis confirms it has been preserved by natural selection alongside humanin, suggesting important biological roles (13).
The success of natural MDPs has inspired the development of synthetic peptides that target mitochondrial function. SS-31 (elamipretide) is a synthetic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH₂) designed to concentrate within the inner mitochondrial membrane by binding cardiolipin, a key structural lipid. This interaction stabilizes mitochondrial cristae, reduces ROS production, preserves electron transport chain efficiency, and enhances ATP synthesis (14).
Elamipretide has demonstrated efficacy across preclinical models of cardiovascular disease, renal injury, and neurodegeneration, and is currently under clinical investigation for mitochondrial disorders (14). Parallel research on NAD+ supplementation and Epithalon (a telomerase-activating peptide) reflects the broader scientific interest in mitochondrial and cellular aging pathways.
MDPs in Metabolic Disease Research
One of the most active areas of MDP research concerns metabolic diseases, particularly type 2 diabetes and obesity. Circulating levels of both humanin and MOTS-c are significantly lower in individuals with obesity, insulin resistance, and type 2 diabetes compared with healthy controls (11). SHLP2 levels also decrease with age, potentially contributing to age-related metabolic decline.
MOTS-c improves glucose tolerance by promoting GLUT4 translocation in muscle tissue, activating AMPK-mediated fatty acid oxidation, and reducing lipid accumulation. Humanin decreases hepatic glucose production and protects pancreatic beta cells from apoptosis in preclinical diabetes models (11). A MOTS-c analog (CB4211) has entered clinical trials for nonalcoholic steatohepatitis (NASH) and obesity, marking a significant translational milestone for the MDP field (8).
All peptides mentioned in this article are available exclusively for laboratory-verified research applications. They have not been evaluated by the FDA and are not intended to diagnose, treat, or prevent any disease.
Mitochondrial-derived peptides (MDPs) are small bioactive microproteins encoded by short open reading frames within mitochondrial DNA. The currently known MDPs include humanin, MOTS-c, and SHLP1–6. They function as signaling molecules that regulate metabolism, stress responses, and cellular survival (4).
How was MOTS-c discovered?
MOTS-c was discovered in 2015 through a computational search for potential small open reading frames in the human 12S ribosomal RNA gene. Researchers identified a 51-base-pair sORF encoding a 16-amino-acid peptide with potent metabolic activity (2).
Why is MOTS-c called an exercise mimetic?
Research demonstrates that MOTS-c activates the AMPK signaling pathway—the same pathway activated by physical exercise—and that exercise itself induces endogenous MOTS-c expression in skeletal muscle. In preclinical studies, MOTS-c administration improved physical capacity and metabolic health markers similar to exercise training (7).
What is the relationship between humanin and Alzheimer’s disease research?
Humanin was originally discovered during a screen for neuroprotective factors against amyloid-beta toxicity, a key component of Alzheimer’s pathology. Subsequent studies have demonstrated that humanin and its analogues protect neurons through multiple mechanisms, including direct amyloid-beta interaction and anti-apoptotic signaling (1, 10).
Do MDP levels change with age?
Yes. Circulating levels of humanin, MOTS-c, and several SHLPs decline with age in humans and mice. Interestingly, this decline does not occur in the long-lived naked mole rat, suggesting MDPs may contribute to differential aging trajectories across species (8).
What is SS-31 and how does it relate to mitochondrial peptides?
SS-31 (elamipretide) is a synthetic mitochondria-targeted tetrapeptide that binds cardiolipin in the inner mitochondrial membrane. While not a natural MDP, it was inspired by the concept of peptide-mediated mitochondrial protection and is currently under clinical investigation for multiple mitochondrial disorders (14).
Are there clinical trials involving mitochondrial-derived peptides?
Yes. CB4211, a MOTS-c analog, has entered clinical trials for NASH and obesity. Elamipretide (SS-31) has been investigated in trials for Barth syndrome, heart failure, and age-related macular degeneration. These represent the first translational efforts for MDP-based therapeutics (8, 14).
References
Hashimoto Y, et al. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer’s disease genes and Abeta. Proc Natl Acad Sci USA. 2001;98(11):6336-6341. PubMed
Kim SJ, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. PubMed
Cobb LJ, et al. Naturally occurring mitochondrial-derived peptides are age-dependent regulators of apoptosis, insulin sensitivity, and inflammatory markers. Aging. 2016;8(4):796-809. PubMed
Miller B, et al. Peptides derived from small mitochondrial open reading frames: genomic, biological, and therapeutic implications. Exp Cell Res. 2020;393(2):112056. PubMed
Yang B, et al. MOTS-c interacts synergistically with exercise intervention to regulate PGC-1α expression, attenuate insulin resistance and enhance glucose metabolism in mice via AMPK signaling pathway. Biochim Biophys Acta Mol Basis Dis. 2021;1867(6):166126. PubMed
Ran Y, et al. Mitochondria-derived peptides: promising microproteins in cardiovascular diseases. Mol Med Rep. 2025;31(5):111. PubMed
Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470. PubMed
Miller B, et al. Mitochondria-derived peptides in aging and healthspan. J Clin Invest. 2022;132(9):e158449. PubMed
Yin J, et al. Mitochondrial-derived peptide MOTS-c suppresses ovarian cancer progression by attenuating USP7-mediated LARS1 deubiquitination. Adv Sci. 2024;11(45):e2405620. PubMed
Karachaliou CE, Livaniou E. Neuroprotective action of humanin and humanin analogues: research findings and perspectives. Biology. 2023;12(12):1534. PubMed
Kal S, et al. Mitochondrial-derived peptides: antidiabetic functions and evolutionary perspectives. Peptides. 2024;173:171149. PubMed
Kim SJ, et al. Mitochondria-derived peptide SHLP2 regulates energy homeostasis through the activation of hypothalamic neurons. Nat Commun. 2023;14(1):4321. PubMed
Gruschus JM, et al. Evidence of natural selection in the mitochondrial-derived peptides humanin and SHLP6. Sci Rep. 2023;13(1):14110. PubMed
Tung C, et al. Elamipretide: a review of its structure, mechanism of action, and therapeutic potential. Int J Mol Sci. 2025;26(3):944. PubMed
CJC-1295 without DAC is quickly gaining attention for its ability to naturally boost your gh-pulse by supporting the pituitary’s own rhythm, making anti-aging and improved body-composition feel effortless. By mimicking ghrh, this peptide can help enhance sleep quality and promote youthful vitality from the inside out!
Confused about which peptides you can still get? You’re not alone. The FDA has been shaking things up in the peptide world, and keeping track of what’s banned versus what’s available feels like a full-time job. Here’s the deal. Between October 2023 and December 2024, the FDA banned 17 peptides from compounding pharmacies. Some got …
Discover how MOTS‑c, a powerful metabolic peptide, is redefining what it means to support health and vitality from within. Dive into the science of MOTS‑c and unlock effortless ways to enhance well-being, all backed by cutting-edge research.
What Are Mitochondrial-Derived Peptides? MOTS-c, Humanin, and Beyond
Mitochondria are often called the powerhouses of the cell, but recent research has revealed they do far more than generate energy. Buried within the compact 16,569-base-pair mitochondrial genome are small open reading frames (sORFs) that encode a newly recognized class of bioactive signaling molecules called mitochondrial-derived peptides (MDPs). These microproteins—including humanin, MOTS-c, and the small humanin-like peptides (SHLPs)—have emerged as key regulators of metabolism, stress response, and cellular resilience.
Since the discovery of humanin in 2001, the MDP field has expanded rapidly. Researchers have now identified at least nine distinct MDPs, each with unique biological activities that span neuroprotection, insulin sensitization, and exercise-mimetic effects. This article explores what we know about these fascinating molecules and where the research is heading.
All compounds referenced in this article are intended for research purposes only and are not approved for human or animal use. Nothing in this article constitutes medical advice.
The Discovery of Mitochondrial-Derived Peptides
The story of MDPs began when Hashimoto and colleagues screened for genetic factors that protected neurons against amyloid-beta toxicity—a hallmark of Alzheimer’s disease pathology. They identified a cDNA fragment that mapped to the mitochondrial 16S ribosomal RNA gene (MT-RNR2), encoding a 24-amino-acid peptide they named humanin (1). This was groundbreaking: the mitochondrial genome, long assumed to encode only 13 proteins plus transfer and ribosomal RNAs, contained hidden peptide-coding sequences.
The next major breakthrough came in 2015 when Kim et al. discovered MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c), a 16-amino-acid peptide encoded by a sORF within the 12S rRNA gene (MT-RNR1) (2). Shortly after, Cobb et al. (2016) identified six additional peptides within the 16S rRNA gene, naming them small humanin-like peptides 1 through 6 (SHLP1–6) (3). Computational analyses suggest that hundreds of additional MDPs may remain undiscovered within mitochondrial sequences (4).
MOTS-c: The Exercise Mimetic
Among all MDPs, MOTS-c has generated particular excitement for its remarkable metabolic effects. Research demonstrates that MOTS-c functions as an endogenous exercise mimetic, activating many of the same cellular pathways triggered by physical activity.
The primary mechanism involves the folate-AICAR-AMPK pathway. MOTS-c inhibits the folate cycle and de novo purine biosynthesis, leading to accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), a potent endogenous activator of AMP-activated protein kinase (AMPK) (5). Under metabolic stress, MOTS-c translocates to the nucleus where it regulates gene expression through antioxidant response elements (AREs), modulating stress adaptation and metabolic homeostasis (6).
In preclinical models, MOTS-c administration prevented high-fat-diet-induced obesity and insulin resistance in mice, while also improving glucose tolerance and reducing fat accumulation (2). A landmark 2021 study published in Nature Communications demonstrated that exercise induces endogenous MOTS-c expression in both skeletal muscle and circulation, and that late-life MOTS-c treatment (initiated at 23.5 months in mice) significantly improved physical capacity and healthspan markers (7). Circulating MOTS-c levels decline with age in humans and correlate positively with metabolic health indicators (8).
Research has also expanded into oncology: a 2024 study in Advanced Science found that MOTS-c suppresses ovarian cancer progression by attenuating USP7-mediated LARS1 deubiquitination, opening a new avenue of investigation (9).
These compounds are sold for laboratory research use only. They are not intended for human consumption, therapeutic use, or any form of self-administration.
Humanin: The Original Neuroprotector
Humanin remains the most extensively studied MDP, with over two decades of research documenting its cytoprotective properties. This 24-amino-acid peptide operates through both intracellular and extracellular mechanisms:
In C. elegans, overexpression of humanin extends lifespan through FOXO-dependent mechanisms (8). In mouse models, humanin treatment improves metabolic healthspan parameters, reduces inflammatory markers, and offers protection against age-related cognitive decline. Plasma humanin levels decrease significantly with age in humans, and lower levels are associated with type 2 diabetes and cardiovascular dysfunction (8, 11).
Humanin analogues such as HNG (a potent synthetic variant) and colivelin (a hybrid peptide) show enhanced neuroprotective activity in preclinical Alzheimer’s and Parkinson’s disease models, with researchers actively investigating their therapeutic potential (10).
SHLPs: The Expanding Family
The six small humanin-like peptides (SHLP1–6) represent the newest additions to the MDP family. While research is still in its early stages, several intriguing findings have emerged:
SHLP2 has received the most attention. A 2023 Nature Communications study revealed that SHLP2 regulates energy homeostasis by binding chemokine receptor 7 (CXCR7) and activating pro-opiomelanocortin (POMC) neurons in the hypothalamic arcuate nucleus, suppressing food intake and promoting thermogenesis (12). Both systemic and intracerebroventricular SHLP2 administration protected mice from high-fat-diet-induced obesity and improved insulin sensitivity. SHLP2 also exhibits chaperone-like activity and reduces amyloid-beta toxicity in vitro (3).
SHLP3 supports mitochondrial health by reducing reactive oxygen species (ROS), promoting adipocyte differentiation, and downregulating metabolic and inflammatory markers (8). In contrast, SHLP6 appears to promote apoptosis, and evolutionary analysis confirms it has been preserved by natural selection alongside humanin, suggesting important biological roles (13).
Beyond Natural MDPs: Mitochondria-Targeted Peptides
The success of natural MDPs has inspired the development of synthetic peptides that target mitochondrial function. SS-31 (elamipretide) is a synthetic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH₂) designed to concentrate within the inner mitochondrial membrane by binding cardiolipin, a key structural lipid. This interaction stabilizes mitochondrial cristae, reduces ROS production, preserves electron transport chain efficiency, and enhances ATP synthesis (14).
Elamipretide has demonstrated efficacy across preclinical models of cardiovascular disease, renal injury, and neurodegeneration, and is currently under clinical investigation for mitochondrial disorders (14). Parallel research on NAD+ supplementation and Epithalon (a telomerase-activating peptide) reflects the broader scientific interest in mitochondrial and cellular aging pathways.
MDPs in Metabolic Disease Research
One of the most active areas of MDP research concerns metabolic diseases, particularly type 2 diabetes and obesity. Circulating levels of both humanin and MOTS-c are significantly lower in individuals with obesity, insulin resistance, and type 2 diabetes compared with healthy controls (11). SHLP2 levels also decrease with age, potentially contributing to age-related metabolic decline.
MOTS-c improves glucose tolerance by promoting GLUT4 translocation in muscle tissue, activating AMPK-mediated fatty acid oxidation, and reducing lipid accumulation. Humanin decreases hepatic glucose production and protects pancreatic beta cells from apoptosis in preclinical diabetes models (11). A MOTS-c analog (CB4211) has entered clinical trials for nonalcoholic steatohepatitis (NASH) and obesity, marking a significant translational milestone for the MDP field (8).
All peptides mentioned in this article are available exclusively for laboratory-verified research applications. They have not been evaluated by the FDA and are not intended to diagnose, treat, or prevent any disease.
Frequently Asked Questions
What are mitochondrial-derived peptides?
Mitochondrial-derived peptides (MDPs) are small bioactive microproteins encoded by short open reading frames within mitochondrial DNA. The currently known MDPs include humanin, MOTS-c, and SHLP1–6. They function as signaling molecules that regulate metabolism, stress responses, and cellular survival (4).
How was MOTS-c discovered?
MOTS-c was discovered in 2015 through a computational search for potential small open reading frames in the human 12S ribosomal RNA gene. Researchers identified a 51-base-pair sORF encoding a 16-amino-acid peptide with potent metabolic activity (2).
Why is MOTS-c called an exercise mimetic?
Research demonstrates that MOTS-c activates the AMPK signaling pathway—the same pathway activated by physical exercise—and that exercise itself induces endogenous MOTS-c expression in skeletal muscle. In preclinical studies, MOTS-c administration improved physical capacity and metabolic health markers similar to exercise training (7).
What is the relationship between humanin and Alzheimer’s disease research?
Humanin was originally discovered during a screen for neuroprotective factors against amyloid-beta toxicity, a key component of Alzheimer’s pathology. Subsequent studies have demonstrated that humanin and its analogues protect neurons through multiple mechanisms, including direct amyloid-beta interaction and anti-apoptotic signaling (1, 10).
Do MDP levels change with age?
Yes. Circulating levels of humanin, MOTS-c, and several SHLPs decline with age in humans and mice. Interestingly, this decline does not occur in the long-lived naked mole rat, suggesting MDPs may contribute to differential aging trajectories across species (8).
What is SS-31 and how does it relate to mitochondrial peptides?
SS-31 (elamipretide) is a synthetic mitochondria-targeted tetrapeptide that binds cardiolipin in the inner mitochondrial membrane. While not a natural MDP, it was inspired by the concept of peptide-mediated mitochondrial protection and is currently under clinical investigation for multiple mitochondrial disorders (14).
Are there clinical trials involving mitochondrial-derived peptides?
Yes. CB4211, a MOTS-c analog, has entered clinical trials for NASH and obesity. Elamipretide (SS-31) has been investigated in trials for Barth syndrome, heart failure, and age-related macular degeneration. These represent the first translational efforts for MDP-based therapeutics (8, 14).
References
2 Day FAST Shipping
99%+ Purity Tests
Ships from Gilbert Arizona
USA Lab Tested
Free bacteriostatic water with every order.
Related Posts
CJC-1295 Without DAC: Effortless Anti-Aging & GH-Pulse Boost
CJC-1295 without DAC is quickly gaining attention for its ability to naturally boost your gh-pulse by supporting the pituitary’s own rhythm, making anti-aging and improved body-composition feel effortless. By mimicking ghrh, this peptide can help enhance sleep quality and promote youthful vitality from the inside out!
Which Peptides Did FDA Ban?
Confused about which peptides you can still get? You’re not alone. The FDA has been shaking things up in the peptide world, and keeping track of what’s banned versus what’s available feels like a full-time job. Here’s the deal. Between October 2023 and December 2024, the FDA banned 17 peptides from compounding pharmacies. Some got …
MOTS‑c Metabolic Peptide: Effortless Way to Best Health
Discover how MOTS‑c, a powerful metabolic peptide, is redefining what it means to support health and vitality from within. Dive into the science of MOTS‑c and unlock effortless ways to enhance well-being, all backed by cutting-edge research.